Exelixis, Inc. (NASDAQ:EXEL – Get Free Report)’s stock price shot up 6.7% during trading on Wednesday after Piper Sandler raised their price target on the stock from $37.00 to $38.00. Piper Sandler currently has an overweight rating on the stock. Exelixis traded as high as $35.37 and last traded at $35.01. 649,341 shares traded hands during mid-day trading, a decline of 73% from the average session volume of 2,427,834 shares. The stock had previously closed at $32.81.
A number of other research firms have also recently commented on EXEL. Oppenheimer cut shares of Exelixis from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $41.00 to $33.00 in a research note on Friday, January 24th. Guggenheim reaffirmed a “buy” rating on shares of Exelixis in a research report on Wednesday, January 22nd. BMO Capital Markets cut shares of Exelixis from an “outperform” rating to a “market perform” rating and upped their price target for the stock from $36.00 to $40.00 in a research report on Friday, December 20th. Bank of America cut shares of Exelixis from a “buy” rating to a “neutral” rating and upped their price target for the stock from $35.00 to $39.00 in a research report on Tuesday, December 17th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Exelixis in a research report on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, Exelixis has a consensus rating of “Moderate Buy” and a consensus price target of $36.13.
Get Our Latest Stock Report on Exelixis
Insider Buying and Selling
Hedge Funds Weigh In On Exelixis
A number of institutional investors have recently modified their holdings of EXEL. V Square Quantitative Management LLC acquired a new position in shares of Exelixis in the 3rd quarter valued at $30,000. USA Financial Formulas acquired a new position in Exelixis in the 4th quarter valued at $32,000. Principal Securities Inc. increased its stake in Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 373 shares during the period. Kestra Investment Management LLC acquired a new position in Exelixis in the 4th quarter valued at $39,000. Finally, Brooklyn Investment Group acquired a new position in Exelixis in the 3rd quarter valued at $42,000. 85.27% of the stock is owned by institutional investors and hedge funds.
Exelixis Stock Performance
The firm’s 50-day simple moving average is $34.30 and its 200 day simple moving average is $30.71. The company has a market capitalization of $9.99 billion, a PE ratio of 22.43, a price-to-earnings-growth ratio of 0.63 and a beta of 0.53.
Exelixis (NASDAQ:EXEL – Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 22.43% and a return on equity of 20.99%. As a group, equities analysts anticipate that Exelixis, Inc. will post 1.74 earnings per share for the current year.
Exelixis Company Profile
Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Further Reading
- Five stocks we like better than Exelixis
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Inflation Persists, But So Do Stock Opportunities: Rally On
- How to buy stock: A step-by-step guide for beginnersĀ
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- Shopify Confirms Stock Uptrend, New Highs in Sight
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.